Skip to main content

Table 2 Human Breast Cancer Models ABBV-176; N = 3 Screen Study

From: ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition

Model ID PRLR Density vs MCF7 Drug Dosesa ABBV-176 Efficacyb ER/PR/HER2 BRCA Status
CTG-1124 0.15 0.2 High (84%) ER+/PR+
BRCA 1 def
CTG-0012 0.75 0.5 High (90%) TNBC
BRCA 1 def
CTG-0869 0.8 0.5 High (93%) TNBC
BRCA 1 mut
CTG-0670 1.64 0.5 High (91%) TNBC
BRCA 1 def, BRCA 2 mut
CTG-0033c 2.06 0.2 High (79%) HER2+
BRCA n.d.
CTG-1171 0.42 0.2 High (82%) TNBC
BRCA 1, 2 mut
CTG-1019 0.37 0.2 High (83%) TNBC
BRCA 1, 2 mut
CTG-1242 3.83 0.2 High (83%) TNBC
BRCA n.d.
CTG-0052 0.46 0.2 Moderate (59%) TNBC
BRCA wild type
CTG-0017 0.27 0.2 Moderate (62%) TNBC
BRCA 1, 2 mut
CTG-1520 0.56 0.5 Low (48%) TNBC
BRCA wild type
  1. BRCA breast cancer DNA associated repair gene, def deficient, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IP intraperitoneal, mut mutation, n.d. not determined, PR progesterone receptor, TGI tumor growth inhibition, TNBC triple negative breast cancer
  2. aDoses were administered IP Q7D × 3, at the dose level indicated in mg/kg
  3. bLow = 25–50% TGI, Moderate = 50–75% TGI, High > 75% TGI compared to control PBD ADC treated group (p < 0.0001)
  4. cThis study was performed with larger size treatment groups (N = 6)